期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子标志物预测乳腺癌治疗疗效的研究进展 被引量：4

Resent research about the molecular markers predicting the treatment efficacy of breast cnacer
下载PDF
导出
摘要 乳腺癌是多种基因发生突变所导致的复杂疾病,尽早检出预后不佳的高危病人,及时给予合理的治疗,对于改善乳腺癌病人的预后有重要意义。本文通过综合国内外近年来发表的有代表性的有关乳腺癌分子标志物的文献资料,对乳腺癌预后分子标志物的研究进展进行总结,探讨这些分子标志物与乳腺癌治疗疗效及预后的关系。 Breast cancer is is caused by mutations in multiple genes of complex diseases.Early detection of high-risk patients with poor prognosis,given reasonable and timely treatment,to improve for prognosis is significant important in breast cancer.In this paper,we review the comprehensive published representative literature at home and abroad in recent years about breast cancer of molecular markers,and give a summary for the progress of breast cancer research about prognostic molecular markers,and discuss the relationship between these molecular markers and breast cancer prognosis.
作者 陈东波 张科芝 李俊
机构地区 安徽医科大学第一附属医院肿瘤内科
出处 《现代肿瘤医学》 CAS 2012年第1期209-212,共4页 Journal of Modern Oncology
关键词 乳腺癌 分子标志物 预后 治疗疗效 breast cancer molecular markers prognosis treatment efficacy.
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献43

  • 1Ford CE,Ekstrom EJ,Andersson T.Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells[J].Proc Natl Acad Sci USA,2009,106(10):3919-3924.
  • 2Boccardo F,Guglielmini P,Parodi A,et al.Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive,oestrogen receptor-positive breast cancer patients.Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer[J].Breast Cancer Res Treat,2011,126(3):653-661.
  • 3Aebi S,Sun Z,Braun D,et al.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors:Long-term follow up on IBCSG Trial IX[J].Ann Oncol,2011,1:31.
  • 4Aebi S,Sun Z,Braun D,et al.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors:Long-term follow up on IBCSG TrialIX[J].Ann Oncol,2011,1:31.
  • 5Albert JM,Gonzalez-Angulo AM,Guray M,et al.Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer[J].Cancer,2010,11:8.
  • 6Hussein MR,Abd-Elwahed SR,Abdulwahed AR.Alterations of estrogen receptors,progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast[J].Cell Biol Int,2008,32(6):698-707.
  • 7Lehr HA,Schaefer SC,Delaloye JF.Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer[J].Rev Med Suisse,2009,5(211):1525-1529.
  • 8Chen H,Pimienta G,Gu Y,et al.Proteomic characterization of Her2/neu-overexpressing breast cancer cells[J].Proteomics,2010,10(21):3800-3810.
  • 9Sivridis E,Stamos C,Fiska A,et al.c-erbB-2 and the "triple-state" in early breast carcinomas[J].Med Oncol,2010,27(3):578-584.
  • 10Chen XS,Ma CD,Wu JY,et al.Molecular subtype approximated by quantitative estrogen receptor,progesterone receptor and Her2 can predict the prognosis of breast cancer[J].Tumori,2010,96(1):103-110.

同被引文献44

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：163
  • 2Akarolo-Anthony Sally N,Ogundiran Temidayo O,Adebamowo Clement A.Emerging breast cancer epidemic;evidence from Africa[J].Breast Cancer Res,2010,12(Z4):8.
  • 3Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22:1736-1747.
  • 4Chad A Livasy,Gamze Karaca,Rita Nanda,et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J].Modern Pathol,2006,19(2):264-271.
  • 5Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
  • 6Yang HJ,Yu XF,He XM,et al.Age interactions in breast cancer:an analysis of a 10-year multicentre study in China[J].J Int Med Res,2012,40(3):1130-1140.
  • 7Lakhani SR,Reis-Filho JS,Fulford L,et al.Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype[J].Clin Cancer Res,2005,11(14):5175-5180.
  • 8Molyneux G,Regan J,Smalley MJ.Mammary stem cells and breast cancer[J].Cell Molecular Life Sci,2007,64(24):3248-3260.
  • 9Adedayo A Onitilo,Jessica M Engel,Robert T,et al.Breast cancer subtypes based on ER/PR and HER-2 expression:Comparison of clinicopathologic features and survival[J].Clin Med & Res,2009,7(1-2):4-13.
  • 10曾红艳,曹永政,彭格红,陶文鸿,唐文台.乳腺癌超声征象与ER、PR、C-erbB-2表达的相关性研究[J].中国医学影像技术,2007,23(12):1827-1830. 被引量：36

引证文献4

二级引证文献22

现代肿瘤医学
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部